Engaging with Clinicians
We conduct comparative clinical and cost-effectiveness analyses of health care interventions, such as drugs, devices, and diagnostics. Critical to this process is the feedback we receive from medical professionals in each disease area on the current practices and outcomes that matter most to patients. Our close collaboration with clinicians is essential to ensuring that patients receive the best care possible.
We routinely engage with with academic experts in clinical synthesis and health economics modeling. Additionally, transparency is of the utmost importance to us, and we have extensive policies on reporting any conflicts of interest.
- Our 2018 recommendations to broaden access to CAR-T therapy
- Our 2017 PCSK9 conclusions were covered by the American College of Cardiology; we updated our PCSK9 analysis in 2019
- The September 2019 FDA Advisory Committee peanut allergy results reflected the same concerns ICER surfaced in our July 2019 peanut allergy assessment
Dr. Brad Rovin’s Experience with ICER’s Lupus Nephritis Assessment
Dr. Rovin is a Professor of Medicine and Pathology at Ohio State University Wexner Medical Center.
Medical professionals routinely help us as:
- Experts during our draft scope phase that explain the nuances of each disease area
- Panelists during our public meetings who provide background on the disease of interest
- Public commenters on ongoing reviews that challenge assumptions or provide additional clinical data to be considered. Click here to learn about the data that is most helpful during our reviews.
ICER’s Podcast: A Prescription For Fair Drug Pricing
Additionally, we created a podcast for physicians looking to learn more about ICER’s analyses.
Neurologist Dr. Jason Crowell sits down with ICER’s President, Dr. Steve Pearson, to pry open the black box of US drug pricing and to wrestle with each of the financial and ethical tensions that undergird our current medical infrastructure. They dive into why prescription drugs are so expensive in our country, uncover the tradeoffs that American patients face when they can’t afford drugs, explore how other countries use clinical data to ensure a drug’s price reflects how well it works, and recommend individual steps that all of us can take – from physicians to patients to policymakers – to achieve both fair pricing and fair access across the US health system. A must-listen for physicians who are concerned that prescription drugs not only can have health side effects, but financial side effects, too.